An emulated trial to study the impact of dipeptidyl peptidase 4 inhibitors on dementia risk in T2DM patients – a retrospective cohort study
Description: Objectives: To compare the dementia risk in T2DM patients newly treated with dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) with others second line T2DM medications, and to compare the effectiveness of dementia risk reduction in T2DM patients among DPP-4 inhibitors.
Hypothesis to be tested: DPP-4 inhibitors can reduce dementia risk in T2DM patients.
Design and subjects: This study is an emulated trial using population-based data in the Hospital Authority. Patients diagnosed with T2DM, aged 60 years or above, without dementia, and had no previous treatment with any second line or third line medications for T2DM will be included. Subjects will be enrolled between 2009 and 2018. The treatment group includes subjects newly prescribed with any DPP-4 inhibitors. The control group includes subjects newly prescribed with any other second line T2DM medications. Subjects will be followed for at least five years. Subjects will be identified from the Clinical Data Analysis and Reporting System (CDARS), and their diagnosis and prescription records in CDARS will be used to screen for eligibility and to determine the study outcome. We will use statistical approaches to to emulate two comparable (comparability/exchangeability) at baseline.
Main outcome measures: Five-years dementia incidence in the treatment and control groups, and 5-years dementia incidence in subjects treated with different DPP-4 inhibitors.
Data analysis and expected results: Dementia risk in the treatment and control groups will be compared by Cox proportional hazards regression analysis. We expect hazard ratio of less than 1.
Funder: Health and Medical Research Fund
Amount: HKD 493,000
Funding type: grant
Funder scheme: HMRF - Health and Health Services (including HHSRF)
Start date: 2022-01-01
Investigator: Benjamin Hon-kei YIP (lead)
Institutions: Chinese University of Hong Kong, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 21220611
OpenAlex ID: G1280465795
